RU2329263C2 - Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с - Google Patents
Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с Download PDFInfo
- Publication number
- RU2329263C2 RU2329263C2 RU2003115429/04A RU2003115429A RU2329263C2 RU 2329263 C2 RU2329263 C2 RU 2329263C2 RU 2003115429/04 A RU2003115429/04 A RU 2003115429/04A RU 2003115429 A RU2003115429 A RU 2003115429A RU 2329263 C2 RU2329263 C2 RU 2329263C2
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- denotes
- formula
- group
- compound
- Prior art date
Links
- 102000003923 Protein Kinase C Human genes 0.000 title claims abstract 4
- 108090000315 Protein Kinase C Proteins 0.000 title claims abstract 4
- OCQUNLGTYDFYDP-VURMDHGXSA-N (z)-2-(1h-indol-2-yl)but-2-enedioic acid Chemical compound C1=CC=C2NC(C(/C(O)=O)=C/C(=O)O)=CC2=C1 OCQUNLGTYDFYDP-VURMDHGXSA-N 0.000 title abstract 2
- 150000003949 imides Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 13
- 229910052799 carbon Inorganic materials 0.000 claims abstract 9
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 5
- 229910052736 halogen Inorganic materials 0.000 claims abstract 4
- 150000002367 halogens Chemical class 0.000 claims abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 4
- 230000001154 acute effect Effects 0.000 claims abstract 3
- 230000001684 chronic effect Effects 0.000 claims abstract 3
- 210000000056 organ Anatomy 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 238000011282 treatment Methods 0.000 claims abstract 3
- 230000000694 effects Effects 0.000 claims abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- YINLOZXFQAVUKM-UHFFFAOYSA-N 3-[2-(4-ethylpiperazin-1-yl)quinazolin-4-yl]-4-(1h-indol-3-yl)pyrrole-2,5-dione Chemical compound C1CN(CC)CCN1C1=NC(C=2C(NC(=O)C=2C=2C3=CC=CC=C3NC=2)=O)=C(C=CC=C2)C2=N1 YINLOZXFQAVUKM-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000005936 piperidyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- OAVGBZOFDPFGPJ-UHFFFAOYSA-N sotrastaurin Chemical compound C1CN(C)CCN1C1=NC(C=2C(NC(=O)C=2C=2C3=CC=CC=C3NC=2)=O)=C(C=CC=C2)C2=N1 OAVGBZOFDPFGPJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 15
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- -1 phenylC1-4alkyl Chemical group 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24640000P | 2000-11-07 | 2000-11-07 | |
| US60/246,400 | 2000-11-07 | ||
| US28370501P | 2001-04-13 | 2001-04-13 | |
| US60/283,705 | 2001-04-13 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008105345/04A Division RU2008105345A (ru) | 2000-11-07 | 2008-02-14 | Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003115429A RU2003115429A (ru) | 2004-12-10 |
| RU2329263C2 true RU2329263C2 (ru) | 2008-07-20 |
Family
ID=26937956
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003115429/04A RU2329263C2 (ru) | 2000-11-07 | 2001-11-05 | Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с |
| RU2008105345/04A RU2008105345A (ru) | 2000-11-07 | 2008-02-14 | Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008105345/04A RU2008105345A (ru) | 2000-11-07 | 2008-02-14 | Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с |
Country Status (30)
| Country | Link |
|---|---|
| EP (2) | EP2070921A1 (enExample) |
| JP (1) | JP4234426B2 (enExample) |
| KR (3) | KR100916613B1 (enExample) |
| CN (1) | CN1253449C (enExample) |
| AR (1) | AR035211A1 (enExample) |
| AT (1) | ATE445613T1 (enExample) |
| AU (3) | AU2181002A (enExample) |
| BR (1) | BRPI0115193B1 (enExample) |
| CA (1) | CA2428133C (enExample) |
| CY (1) | CY1110564T1 (enExample) |
| CZ (1) | CZ307144B6 (enExample) |
| DE (1) | DE60140201D1 (enExample) |
| DK (1) | DK1337527T3 (enExample) |
| EC (1) | ECSP104578A (enExample) |
| ES (1) | ES2332770T3 (enExample) |
| HU (1) | HU228999B1 (enExample) |
| IL (3) | IL155618A0 (enExample) |
| MX (1) | MXPA03004037A (enExample) |
| MY (2) | MY127157A (enExample) |
| NO (1) | NO327427B1 (enExample) |
| NZ (2) | NZ525656A (enExample) |
| PE (1) | PE20020544A1 (enExample) |
| PL (1) | PL208794B1 (enExample) |
| PT (1) | PT1337527E (enExample) |
| RU (2) | RU2329263C2 (enExample) |
| SG (1) | SG159378A1 (enExample) |
| SI (1) | SI1337527T1 (enExample) |
| SK (1) | SK287919B6 (enExample) |
| TW (2) | TW200738687A (enExample) |
| WO (1) | WO2002038561A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10995052B2 (en) | 2016-02-03 | 2021-05-04 | Galderma Research & Development | Biaromatic propynyl compounds, pharmaceutical and cosmetic compositions containing same, and uses thereof |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI324064B (en) | 2002-04-03 | 2010-05-01 | Novartis Ag | Indolylmaleimide derivatives |
| ATE409035T1 (de) | 2002-06-05 | 2008-10-15 | Janssen Pharmaceutica Nv | Substituierte pyrroline als kinase inhibitoren |
| US6987110B2 (en) | 2002-06-05 | 2006-01-17 | Janssen Pharmaceutica N.V. | Substituted pyrrolines as kinase inhibitors |
| GB0303319D0 (en) | 2003-02-13 | 2003-03-19 | Novartis Ag | Organic compounds |
| WO2005025602A1 (en) * | 2003-09-16 | 2005-03-24 | Garvan Institute Of Medical Research | METHODS FOR IDENTIFYING MODULATORS OF PROTEIN KINASE C-EPSILON (PKCϵ) AND METHOD OF TREATMENT OF ABERRANT GLUCOSE METABOLISM ASSOCIATED THEREWITH |
| JP2007509185A (ja) * | 2003-10-27 | 2007-04-12 | ノバルティス アクチエンゲゼルシャフト | βアミロイド産生および／または凝集と関係がある神経障害および血管障害の処置のためのインドリル−ピロールジオン誘導体 |
| US7615552B2 (en) * | 2003-11-10 | 2009-11-10 | Synta Pharmaceuticals Corp. | Fused heterocyclic compounds |
| GB0401089D0 (en) * | 2004-01-19 | 2004-02-18 | Novartis Ag | Organic compounds |
| BRPI0506939A (pt) | 2004-01-19 | 2007-06-12 | Novartis Ag | derivados de indolilmaleimida como inibidores de pkc |
| BRPI0509754A (pt) * | 2004-04-08 | 2007-10-16 | Novartis Ag | inibidores de proteìna quinase c para o tratamento de doenças auto-imunes e de rejeição a transplante |
| GB0410713D0 (en) * | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
| AU2005313485B2 (en) | 2004-12-08 | 2011-02-03 | Johannes Gutenberg-Universitat Mainz | 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors |
| GB0504203D0 (en) * | 2005-03-01 | 2005-04-06 | Novartis Ag | Organic compounds |
| GB0507918D0 (en) | 2005-04-19 | 2005-05-25 | Novartis Ag | Organic compounds |
| WO2006117212A2 (en) | 2005-05-04 | 2006-11-09 | Develogen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
| GB0511060D0 (en) | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| ES2396671T3 (es) | 2005-07-11 | 2013-02-25 | Novartis Ag | Derivados de la indolilmaleimida como inhibidores de la proteína quinasa |
| CA2963828A1 (en) | 2005-10-26 | 2007-05-03 | Novartis Ag | Novel use of il-1beta compounds |
| JP2009516671A (ja) | 2005-11-21 | 2009-04-23 | ノバルティス アクチエンゲゼルシャフト | ｍＴＯＲ阻害剤を使用する神経内分泌腫瘍処置 |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| GB0605691D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
| GB0613162D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic compounds |
| US20100179175A1 (en) * | 2006-08-23 | 2010-07-15 | Sivak Jeremy M | Use of pkc inhibitors in ocular diseases |
| MY158026A (en) * | 2006-10-20 | 2016-08-30 | Novartis Ag | Crystal modifications-3-(1h-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2, 5-dione |
| EP2091535A1 (en) * | 2006-12-07 | 2009-08-26 | Novartis AG | Use of pkc inhibitors in transplantation |
| MX2009006533A (es) * | 2006-12-19 | 2009-06-26 | Novartis Ag | Derivados de indolil-maleimida como inhibidores de cinasa. |
| US20100093749A1 (en) * | 2007-03-09 | 2010-04-15 | Novartis Ag | Compounds |
| EP2152308A1 (en) | 2007-05-29 | 2010-02-17 | Novartis Ag | New indications for anti- il-i-beta therapy |
| JP2010540920A (ja) * | 2007-09-27 | 2010-12-24 | ノバルティス アーゲー | 薬物モニタリングアッセイ |
| WO2009060035A1 (en) | 2007-11-08 | 2009-05-14 | Novartis Ag | Gene expression signatures for chronic/sclerosing allograft nephropathy |
| EP2217231B1 (en) | 2007-12-05 | 2011-11-30 | Johannes Gutenberg-Universität Mainz | Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management |
| US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| CA2767616A1 (en) | 2009-07-09 | 2011-01-13 | The Scripps Research Institute | Gene expression profiles associated with chronic allograft nephropathy |
| RU2441000C2 (ru) * | 2009-11-27 | 2012-01-27 | Общество с ограниченной ответственностью "Молекулярные Технологии" | 4-(1-(4-(4-метоксифенилтио)-2,5-диоксо-2,5-дигидро-1н-пирро-3-ил)-1н-индол-3-ил)бутилкарбамимидотиоат и способ его применения |
| EP2338486A1 (en) | 2009-12-18 | 2011-06-29 | Johannes Gutenberg-Universität Mainz | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma |
| EP2343291A1 (en) | 2009-12-18 | 2011-07-13 | Johannes Gutenberg-Universität Mainz | 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment |
| US8791100B2 (en) | 2010-02-02 | 2014-07-29 | Novartis Ag | Aryl benzylamine compounds |
| KR101461767B1 (ko) | 2010-03-30 | 2014-11-13 | 노파르티스 아게 | 만성 활성 ｂ-세포-수용체 신호전달이 있는 ｂ-세포 림프종의 치료를 위한 ｐｋｃ 억제제 |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| EP2474541A1 (en) | 2010-12-23 | 2012-07-11 | Johannes- Gutenberg-Universität Mainz | Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment |
| CN102153605B (zh) * | 2011-03-02 | 2014-02-19 | 福建省微生物研究所 | 一种咪唑立宾的提纯方法 |
| UY34072A (es) * | 2011-05-17 | 2013-01-03 | Novartis Ag | Derivados sustituidos de indol |
| EA201490164A1 (ru) | 2011-06-27 | 2014-04-30 | Новартис Аг | Твердые формы и соли производных тетрагидропиридопиримидина |
| GB201111427D0 (en) * | 2011-07-05 | 2011-08-17 | Amakem Nv | Novel bisindolylmaleimides, pan-pkc inhibitors |
| WO2013008095A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel pyrrolo pyrimidine derivatives |
| US8846712B2 (en) | 2011-09-12 | 2014-09-30 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN103987699A (zh) | 2011-10-21 | 2014-08-13 | 诺华股份有限公司 | 作为pi3k调节剂的喹唑啉衍生物 |
| US20140348848A1 (en) | 2011-12-02 | 2014-11-27 | Dhananjay Kaul | Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease |
| ES2661510T3 (es) | 2011-12-15 | 2018-04-02 | Novartis Ag | Uso de inhibidores de la actividad o función de PI3K |
| SG11201402237WA (en) | 2011-12-22 | 2014-09-26 | Novartis Ag | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives |
| US20150148377A1 (en) | 2011-12-22 | 2015-05-28 | Novartis Ag | Quinoline Derivatives |
| WO2013167403A1 (en) | 2012-05-09 | 2013-11-14 | Sanofi | Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors |
| CA2888194A1 (en) | 2012-11-07 | 2014-05-15 | Novartis Ag | Substituted indole derivatives |
| TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫－吡啶并－□衍生物之固體形式 |
| CN104812415A (zh) * | 2012-11-29 | 2015-07-29 | 诺华股份有限公司 | 药物组合 |
| CA2892927A1 (en) | 2012-12-10 | 2014-06-19 | Centogene Ag | Use of maleimide derivatives for preventing and treating leukemia |
| JP2016508962A (ja) * | 2012-12-10 | 2016-03-24 | セントジーン アーゲー | ガンを予防および治療するためのマレイミド誘導体の使用 |
| WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
| WO2014174478A1 (en) | 2013-04-26 | 2014-10-30 | Novartis Ag | Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor |
| CA2918938C (en) | 2013-09-22 | 2021-05-18 | Calitor Sciences, Llc | Substituted aminopyrimidine compounds and methods of use |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| AU2015235880B2 (en) | 2014-03-28 | 2018-11-01 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| BR112016024533A8 (pt) | 2014-04-24 | 2021-03-30 | Novartis Ag | derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas |
| EA201692140A1 (ru) | 2014-04-24 | 2017-04-28 | Новартис Аг | Производные аминопиридина в качестве ингибиторов фосфатидилинозитол 3-киназы |
| CA2945257A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| US11104951B2 (en) | 2014-05-22 | 2021-08-31 | The Scripps Research Institute | Molecular signatures for distinguishing liver transplant rejections or injuries |
| US10443100B2 (en) | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
| EP3825417A3 (en) | 2014-05-22 | 2021-09-15 | The Scripps Research Institute | Tissue molecular signatures of kidney transplant rejections |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| WO2017029588A2 (en) | 2015-08-14 | 2017-02-23 | Novartis Ag | Pharmaceutical combinations and their use |
| WO2017044434A1 (en) | 2015-09-11 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| EP3187495A1 (en) | 2015-12-30 | 2017-07-05 | Johannes Gutenberg-Universität Mainz | 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment |
| EP3600440A1 (en) | 2017-03-20 | 2020-02-05 | Sienna Biopharmaceuticals, Inc. | Reduced exposure conjugates modulating therapeutic targets |
| WO2018175302A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugates targeting c-src with reduced exposure |
| JP7254076B2 (ja) | 2017-11-19 | 2023-04-07 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | 置換ヘテロアリール化合物及び使用方法 |
| US10751339B2 (en) | 2018-01-20 | 2020-08-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
| CN110551103B (zh) * | 2018-05-30 | 2022-08-23 | 北京大学深圳研究生院 | 一种jak3选择性抑制剂 |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| AU2020279927B2 (en) | 2019-05-23 | 2025-08-21 | Novartis Ag | Crystalline forms of a BTK inhibitor |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0328026A1 (de) * | 1988-02-10 | 1989-08-16 | F. Hoffmann-La Roche Ag | Substituierte Pyrrole |
| RU2126007C1 (ru) * | 1992-05-30 | 1999-02-10 | Гедеке АГ | Производные индолокарбазолимида, смесь их изомеров и их соли, фармацевтическая композиция с активностью, ингибирующей протеинкиназу c или киназу легкой миозиновой цепи или подавляющей иммунные реакции |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7612609A (nl) | 1975-11-12 | 1977-05-16 | Schering Ag | Werkwijze voor het bereiden van 1,3-geoxyge- neerde 8(alpha)-ostratienen. |
| FR2637591B1 (fr) | 1988-10-11 | 1992-10-23 | Synthelabo | Derives de quinoleinone, leur preparation et leur application en therapeutique |
| ATE284387T1 (de) * | 1998-10-08 | 2004-12-15 | Smithkline Beecham Plc | 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) |
| GB9828640D0 (en) * | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
| EP1307447B1 (en) * | 2000-07-27 | 2004-12-15 | F. Hoffmann-La Roche Ag | 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta |
-
2001
- 2001-11-05 AU AU2181002A patent/AU2181002A/xx active Pending
- 2001-11-05 SK SK546-2003A patent/SK287919B6/sk not_active IP Right Cessation
- 2001-11-05 AR ARP010105176A patent/AR035211A1/es not_active Application Discontinuation
- 2001-11-05 KR KR1020067017472A patent/KR100916613B1/ko not_active Expired - Fee Related
- 2001-11-05 MX MXPA03004037A patent/MXPA03004037A/es active IP Right Grant
- 2001-11-05 HU HU0301651A patent/HU228999B1/hu not_active IP Right Cessation
- 2001-11-05 JP JP2002541095A patent/JP4234426B2/ja not_active Expired - Fee Related
- 2001-11-05 SI SI200130954T patent/SI1337527T1/sl unknown
- 2001-11-05 KR KR1020037005805A patent/KR100748386B1/ko not_active Expired - Fee Related
- 2001-11-05 BR BRPI0115193A patent/BRPI0115193B1/pt not_active IP Right Cessation
- 2001-11-05 CN CNB018199925A patent/CN1253449C/zh not_active Expired - Fee Related
- 2001-11-05 EP EP09151894A patent/EP2070921A1/en not_active Withdrawn
- 2001-11-05 SG SG200502844-4A patent/SG159378A1/en unknown
- 2001-11-05 CZ CZ2003-1266A patent/CZ307144B6/cs not_active IP Right Cessation
- 2001-11-05 ES ES01993604T patent/ES2332770T3/es not_active Expired - Lifetime
- 2001-11-05 PT PT01993604T patent/PT1337527E/pt unknown
- 2001-11-05 AU AU2002221810A patent/AU2002221810B2/en not_active Ceased
- 2001-11-05 PE PE2001001093A patent/PE20020544A1/es not_active Application Discontinuation
- 2001-11-05 CA CA002428133A patent/CA2428133C/en not_active Expired - Fee Related
- 2001-11-05 PL PL361409A patent/PL208794B1/pl unknown
- 2001-11-05 WO PCT/EP2001/012785 patent/WO2002038561A1/en not_active Ceased
- 2001-11-05 DE DE60140201T patent/DE60140201D1/de not_active Expired - Lifetime
- 2001-11-05 KR KR1020087002849A patent/KR20080014934A/ko not_active Ceased
- 2001-11-05 EP EP01993604A patent/EP1337527B1/en not_active Expired - Lifetime
- 2001-11-05 IL IL15561801A patent/IL155618A0/xx active IP Right Grant
- 2001-11-05 RU RU2003115429/04A patent/RU2329263C2/ru not_active IP Right Cessation
- 2001-11-05 NZ NZ525656A patent/NZ525656A/xx not_active IP Right Cessation
- 2001-11-05 NZ NZ535616A patent/NZ535616A/xx not_active IP Right Cessation
- 2001-11-05 AT AT01993604T patent/ATE445613T1/de active
- 2001-11-05 DK DK01993604T patent/DK1337527T3/da active
- 2001-11-06 MY MYPI20015097A patent/MY127157A/en unknown
- 2001-11-06 MY MYPI20055681A patent/MY139979A/en unknown
- 2001-11-07 TW TW096118830A patent/TW200738687A/zh unknown
- 2001-11-07 TW TW090127656A patent/TWI290553B/zh not_active IP Right Cessation
-
2003
- 2003-04-28 IL IL155618A patent/IL155618A/en not_active IP Right Cessation
- 2003-05-06 NO NO20032034A patent/NO327427B1/no not_active IP Right Cessation
-
2005
- 2005-06-01 AU AU2005202387A patent/AU2005202387B2/en not_active Ceased
-
2007
- 2007-04-10 IL IL182428A patent/IL182428A0/en unknown
-
2008
- 2008-02-14 RU RU2008105345/04A patent/RU2008105345A/ru not_active Application Discontinuation
-
2009
- 2009-11-25 CY CY20091101228T patent/CY1110564T1/el unknown
-
2010
- 2010-03-11 EC EC2010004578A patent/ECSP104578A/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0328026A1 (de) * | 1988-02-10 | 1989-08-16 | F. Hoffmann-La Roche Ag | Substituierte Pyrrole |
| RU2126007C1 (ru) * | 1992-05-30 | 1999-02-10 | Гедеке АГ | Производные индолокарбазолимида, смесь их изомеров и их соли, фармацевтическая композиция с активностью, ингибирующей протеинкиназу c или киназу легкой миозиновой цепи или подавляющей иммунные реакции |
Non-Patent Citations (2)
| Title |
|---|
| J. of Medicinal Chemistry, v.35, n.1, 1992, p.177-184. * |
| приоритет от 07.11.2000 по п.1, где R означает группу формулы d) и формулы е) и Е означает -N=, a G означает -СН=, а также соединения по примерам 165, 168, 169. приоритет от 13.04.2001 по п.1, где R означает группу формулы е) и Е означает -СН=, a G означает -N=. Приоритет от 07.11.2000 и от 13.04.2001 для пп.2-10 в равной степени. * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10995052B2 (en) | 2016-02-03 | 2021-05-04 | Galderma Research & Development | Biaromatic propynyl compounds, pharmaceutical and cosmetic compositions containing same, and uses thereof |
| RU2753863C2 (ru) * | 2016-02-03 | 2021-08-24 | Галдерма Ресерч Энд Девелопмент | Новые биароматические соединения пропинила, фармацевтические и косметические композиции, их содержащие, и их применение |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2329263C2 (ru) | Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с | |
| RU2003115429A (ru) | Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с | |
| RU2394826C2 (ru) | Дизамещенные пиразолобензодиазепины, используемые в качестве ингибиторов cdk2 и ангиогенеза, а также для лечения злокачественных новообразований молочной железы, толстого кишечника, легкого и предстательной железы | |
| RU2430923C2 (ru) | Тиазолилдигидрохиназолины | |
| RU2336275C2 (ru) | Пиримидопроизводные, характеризующиеся антипролиферативной активностью, и фармацевтическая композиция | |
| RU2356891C2 (ru) | Производные пиридинкарбоксамида и их соли для применения в качестве инсектицида | |
| RU2401260C2 (ru) | Пиримидиновые производные | |
| RU2004132203A (ru) | Индолилмалеимидные производные | |
| RU2007139453A (ru) | Гетеробициклические ингибиторы вируса гепатита с (hcv) | |
| ATE472537T1 (de) | 2,4-di(hetero-)arylamino(-oxy)-5-substituierte pyrimidinderivate als antineoplastika | |
| RU2009101298A (ru) | Гетероциклические соединения в качестве усилителей подслащивающего вещества | |
| RU2004106783A (ru) | Производные 4-амино-6-фенилпирроло[2, 3] пиримидина | |
| JP2004513168A5 (enExample) | ||
| ATE448226T1 (de) | Aza heterocyclische derivate und ihre therapeutische verwendung | |
| RU2395507C2 (ru) | Пиримидиновые производные | |
| EA200100766A1 (ru) | Хинолин-2-он замещенные гетероарильные производные, используемые в качестве противоопухолевых агентов | |
| JP2004522755A5 (enExample) | ||
| RU2003102389A (ru) | Замещенные производные хиназолина и их применение в качестве ингибиторов | |
| WO2001038324A3 (en) | Imidazole derivatives and their use as raf kinase inhibitors | |
| RU2009115963A (ru) | Производные оксадиазола, обладающие противовоспалительными и иммунодепрессантными свойствами | |
| RU2006112593A (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 и/или syk | |
| JP2005508336A5 (enExample) | ||
| RU2004130488A (ru) | Пиримидиновые производные | |
| RU2007100134A (ru) | Пиразолпиримидины | |
| RU2006128788A (ru) | Производные фенил[4-(3-фенил-1н-пиразол-4-ил)пиримидин-2-ил] амина в качестве igf-1r ингибиторов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20171106 |